Logo image of CYTH

CYCLO THERAPEUTICS INC (CYTH) Stock Fundamental Analysis

NASDAQ:CYTH - Nasdaq - US23254X2018 - Common Stock - Currency: USD

0.9385  +0.01 (+0.91%)

Fundamental Rating

2

Taking everything into account, CYTH scores 2 out of 10 in our fundamental rating. CYTH was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTH have multiple concerns. CYTH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CYTH had negative earnings in the past year.
In the past year CYTH has reported a negative cash flow from operations.
In the past 5 years CYTH always reported negative net income.
CYTH had a negative operating cash flow in each of the past 5 years.
CYTH Yearly Net Income VS EBIT VS OCF VS FCFCYTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of CYTH (-472.02%) is worse than 97.70% of its industry peers.
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROIC N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
CYTH Yearly ROA, ROE, ROICCYTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

1.3 Margins

CYTH has a Gross Margin of 91.24%. This is amongst the best in the industry. CYTH outperforms 93.45% of its industry peers.
In the last couple of years the Gross Margin of CYTH has remained more or less at the same level.
CYTH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
CYTH Yearly Profit, Operating, Gross MarginsCYTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

CYTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYTH has more shares outstanding
The number of shares outstanding for CYTH has been increased compared to 5 years ago.
There is no outstanding debt for CYTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYTH Yearly Shares OutstandingCYTH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CYTH Yearly Total Debt VS Total AssetsCYTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -45.34, we must say that CYTH is in the distress zone and has some risk of bankruptcy.
CYTH has a Altman-Z score of -45.34. This is amonst the worse of the industry: CYTH underperforms 94.34% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -45.34
ROIC/WACCN/A
WACC9.4%
CYTH Yearly LT Debt VS Equity VS FCFCYTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

CYTH has a Current Ratio of 0.17. This is a bad value and indicates that CYTH is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.17, CYTH is doing worse than 97.70% of the companies in the same industry.
A Quick Ratio of 0.16 indicates that CYTH may have some problems paying its short term obligations.
The Quick ratio of CYTH (0.16) is worse than 97.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.16
CYTH Yearly Current Assets VS Current LiabilitesCYTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.88% over the past year.
The Revenue has decreased by -8.87% in the past year.
The Revenue has been growing slightly by 1.28% on average over the past years.
EPS 1Y (TTM)44.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.33%
Revenue 1Y (TTM)-8.87%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.97%

3.2 Future

The Earnings Per Share is expected to grow by 20.87% on average over the next years. This is a very strong growth
CYTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 106.48% yearly.
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CYTH Yearly Revenue VS EstimatesCYTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M
CYTH Yearly EPS VS EstimatesCYTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYTH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTH Price Earnings VS Forward Price EarningsCYTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTH Per share dataCYTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as CYTH's earnings are expected to grow with 20.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.49%
EPS Next 3Y20.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLO THERAPEUTICS INC

NASDAQ:CYTH (2/11/2025, 12:14:22 PM)

0.9385

+0.01 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners13.03%
Inst Owner Change-34.85%
Ins Owners8.57%
Ins Owner Change1.65%
Market Cap30.73M
Analysts77.78
Price Target0.97 (3.36%)
Short Float %0.64%
Short Ratio2.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.89%
Min EPS beat(2)-68.96%
Max EPS beat(2)-32.83%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.61%
Min Revenue beat(2)-54.92%
Max Revenue beat(2)-22.3%
Revenue beat(4)0
Avg Revenue beat(4)-39.05%
Min Revenue beat(4)-54.92%
Max Revenue beat(4)-22.3%
Revenue beat(8)1
Avg Revenue beat(8)-43.22%
Revenue beat(12)2
Avg Revenue beat(12)-33.37%
Revenue beat(16)3
Avg Revenue beat(16)-29.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.24%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 35.29
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0.03
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.24%
FCFM N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
F-Score3
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.16
Altman-Z -45.34
F-Score3
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)70.85%
Cap/Depr(5y)142.51%
Cap/Sales(3y)0.98%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.33%
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.87%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.97%
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A
EBIT growth 1Y-27.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.22%
OCF growth 3YN/A
OCF growth 5YN/A